{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:09:55Z","timestamp":1789582195296,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["A20D3b0073"],"award-info":[{"award-number":["A20D3b0073"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007672","name":"Mechanobiology Institute, Singapore","doi-asserted-by":"publisher","award":["A-0003467-22-00"],"award-info":[{"award-number":["A-0003467-22-00"]}],"id":[{"id":"10.13039\/501100007672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX09101001-002\u2013044"],"award-info":[{"award-number":["2017ZX09101001-002\u2013044"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025841","name":"Imagine America Foundation","doi-asserted-by":"publisher","award":["H18\/01\/a0\/017"],"award-info":[{"award-number":["H18\/01\/a0\/017"]}],"id":[{"id":"10.13039\/100025841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.dsx.2023.102921","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:44:15Z","timestamp":1702471455000},"page":"102921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-5710","authenticated-orcid":false,"given":"Shanshan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu Goutham","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik Mitra","family":"Venkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Tasnim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanry","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dsx.2023.102921_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dsx.2023.102921_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.dsx.2023.102921_bib4","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2023.102921_bib5","article-title":"Controversies and opportunities in the use of inflammatory markers for diagnosis or risk prediction in fatty liver disease","volume":"11","author":"Lambrecht","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib6","first-page":"40","article-title":"Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail","volume":"9","author":"Sharma","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102921_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.105","article-title":"Drug discovery and treatment paradigms in nonalcoholic steatohepatitis","volume":"3","author":"Noureddin","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"10.1016\/j.dsx.2023.102921_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dsx.2023.102921_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.101014","article-title":"Therapeutic drug monitoring (TDM) as intervention: a cross-sectional analysis of characteristics of 173 registered clinical trials","volume":"30","author":"Zhao","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib10","first-page":"51","article-title":"New drugs on the block-emerging treatments for nonalcoholic steatohepatitis","volume":"9","author":"Stojsavljevic-Shapeski","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12072-019-10001-4","article-title":"New drugs for NAFLD: lessons from basic models to the clinic","volume":"14","author":"Reimer","year":"2020","journal-title":"Hepatol Int"},{"issue":"13","key":"10.1016\/j.dsx.2023.102921_bib12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14656566.2020.1774553","article-title":"Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis","volume":"21","author":"Lambrecht","year":"2020","journal-title":"Expet Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/med.21515","article-title":"Progress and challenges in the prevention and control of nonalcoholic fatty liver disease","volume":"39","author":"Cai","year":"2019","journal-title":"Med Res Rev"},{"key":"10.1016\/j.dsx.2023.102921_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155264","article-title":"Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: an overview and current perspectives","volume":"134","author":"Yan","year":"2022","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.dsx.2023.102921_bib15","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metabol Syndr"},{"issue":"9","key":"10.1016\/j.dsx.2023.102921_bib16","article-title":"Decoding the pathophysiology of non-alcoholic fatty liver disease progressing to non-alcoholic steatohepatitis: a systematic review","volume":"13","author":"Yaqub","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12967-022-03693-0","article-title":"Mitochondrial transplantation: opportunities and challenges in the treatment of obesity, diabetes, and nonalcoholic fatty liver disease","volume":"20","author":"Chen","year":"2022","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002243","article-title":"Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes","volume":"9","author":"Loosen","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvm016","article-title":"FXR-mediated regulation of eNOS expression in vascular endothelial cells","volume":"77","author":"Li","year":"2008","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.dsx.2023.102921_bib20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102921_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10565-020-09544-2","article-title":"Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists","volume":"37","author":"Boeckmans","year":"2021","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.dsx.2023.102921_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106174","article-title":"Semaglutide for the treatment of non-alcoholic steatohepatitis: trial design and comparison of non-invasive biomarkers","volume":"97","author":"Harrison","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12951-021-01205-8","article-title":"Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma","volume":"20","author":"Yu","year":"2022","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102921_bib24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/1574887113666180227100217","article-title":"Pharmacology, systematic review and recent clinical trials of metadoxine","volume":"13","author":"Di Miceli","year":"2018","journal-title":"Rev Recent Clin Trials"},{"issue":"11","key":"10.1016\/j.dsx.2023.102921_bib25","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/dom.14499","article-title":"Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) indiawith type 2 diabetes: a randomized, placebo-controlled trial","volume":"23","author":"Eldor","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2023.102921_bib26","series-title":"Zydus' saroglitazar becomes first NASH drug approved globally","author":"Nawrat","year":"2020"},{"issue":"1","key":"10.1016\/j.dsx.2023.102921_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","article-title":"Animal models of nonalcoholic fatty liver disease","volume":"8","author":"Hebbard","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102921_bib28","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41401-021-00832-z","article-title":"NASH: regulatory considerations for clinical drug development and U.S. FDA approval","volume":"43","author":"Harvey","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.dsx.2023.102921_bib29","article-title":"Reactive oxygen species induce fatty liver and ischemia-reperfusion injury by promoting inflammation and cell death","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102921_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020386","article-title":"Network-based assessment of adverse drug reaction risk in polypharmacy using high-throughput screening data","volume":"20","author":"de Anda-Jauregui","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dsx.2023.102921_bib31","series-title":"Developing drugs for treatment guidance for industry","year":"2019"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123002175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123002175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:26:05Z","timestamp":1761729965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123002175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1871402123002175"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102921","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102921"}}